Management of metastatic thyroid cancer in pregnancy: risk and uncertainty

Christopher W Rowe1,4, Kirsten Murray1, Andrew Woods2, Sandeep Gupta3,5, Roger Smith1,4 and Katie Wynne1,4

1Departments of Endocrinology and Diabetes and 2Maternity and Gynaecology, John Hunter Hospital, Newcastle, New South Wales, Australia, 3Department of Nuclear Medicine & PET, Hunter New England Imaging, John Hunter and Calvary Mater Hospital, Newcastle, New South Wales, Australia, 4Schools of Medicine and Public Health, and 5Health Sciences, University of Newcastle, Newcastle, New South Wales, Australia

Summary

Metastatic thyroid cancer is an uncommon condition to be present at the time of pregnancy, but presents a challenging paradigm of care. Clinicians must balance the competing interests of long-term maternal health, best achieved by iatrogenic hyperthyroidism, regular radioiodine therapy and avoidance of dietary iodine, against the priority to care for the developing foetus, with inevitable compromise. Additionally, epidemiological and cellular data support the role of oestrogen as a growth factor for benign and malignant thyrocytes, although communicating the magnitude of this risk to patients and caregivers, as well as the uncertain impact of any pregnancy on long-term prognosis, remains challenging. Evidence to support treatment decisions in this uncommon situation is presented in the context of a case of a pregnant teenager with known metastatic papillary thyroid cancer and recent radioiodine therapy.

Learning points:

• Pregnancy is associated with the growth of thyroid nodules due to stimulation from oestrogen receptors on thyrocytes and HCG cross-stimulation of the TSH receptor.
• Thyroid cancer diagnosed during pregnancy has not been shown to be associated with increased rates of persistent or recurrent disease in most studies.
• There is little evidence to guide the management of metastatic thyroid cancer in pregnancy, where both maternal and foetal wellbeing must be carefully balanced.

Background

Thyroid cancer is the most common endocrine malignancy, and the second most common invasive malignancy complicating pregnancy, occurring in 1 of 1000 pregnancies (1). Compared with other solid organ malignancies such as breast cancer, thyroid cancer presents unique management challenges due to its usually slow proliferation rate, the efficacy of surgery and radioiodine as curative first-line treatment and poor response to standard chemotherapy. The majority of thyroid cancer patients present with localised disease, and widespread metastases are relatively uncommon, especially in women of childbearing age. The published reviews and case series of thyroid cancer in pregnancy focus predominantly on the more common situation of establishing the diagnosis of a suspicious thyroid nodule, and whether definitive therapy can be safely deferred until post-partum (1, 2). Thus, there is a paucity of information to guide clinicians caring for patients with metastatic thyroid cancer during
pregnancy. We present the management of a pregnant patient with known metastatic papillary thyroid cancer (PTC) and recent radioiodine therapy and review the literature regarding risks of disease progression in pregnancy, endocrine management considerations and potential conflicts between maternal and foetal wellbeing.

Case presentation

The patient, a 16-year-old female, presented six weeks pregnant, having self-ceasing prescribed levothyroxine (1250 µg/week) at conception. Serum biochemistry confirmed pregnancy and noted a thyroid-stimulating hormone (TSH) level of 171.6 IU/L (local first trimester reference range 0.4–2.5), undetectable free T4 and thyroglobulin 636 µg/L (reference <30).

Six years prior to this presentation (at age 10), she was diagnosed with sporadic PTC. There was no history suggesting a familial tumour syndrome, and she had no other medical history. Total thyroidectomy revealed a unifocal 35 mm left lobe tumour with extrathyroidal extension and ipsilateral lymph node metastases in the lateral neck. Post-operative $^{131}$I-whole body scan (WBS) (Fig. 1A) identified residual uptake in the thyroid bed and contralateral lower neck, and she was treated with $^{131}$I (3.01 GBq). Stimulated thyroglobulin was 786 µg/L, and fell to 39 µg/L on levothyroxine (TSH 1.2 IU/L).

Imaging 12 months later (Fig. 1B) revealed iodine-avid lung metastases, treated with four further doses of $^{131}$I, with the most recent dosimetry-adjusted dose of 9.9 GBq after TSH withdrawal (Fig. 1E) administered 7 months prior to this presentation with pregnancy (lifetime cumulative dose 25.2 GBq). Suppressed thyroglobulin level prior to this dose was 19 µg/L.

Treatment

Between 6 and 14 weeks of gestation, extensive discussion occurred between the patient, her partner, her father and a multidisciplinary medical team. Issues discussed included profound hypothyroidism at the time of conception, risk of progression of metastases due to pregnancy and risks to maternal health due to delayed further treatment, risk of premature delivery due to maternal ill health and the guarded long-term prognosis of the patient. The patient decided to continue the pregnancy, supported by her partner and her father.

In addition to standard obstetric care for a high-risk pregnancy, levothyroxine was titrated aiming for TSH suppression (<0.1 IU/L) and a free T4 level close to the upper limit of the reference range for pregnancy. Dose escalation of levothyroxine was required from 1100 µg/week at presentation to 1500 µg/week by delivery. Control of TSH, and relationship with thyroglobulin during and after pregnancy, are summarised in Fig. 2. Maternal iron deficiency was managed with oral iron supplementation; however, a subsequent rise in TSH at this time raised the possibility of malabsorption of levothyroxine due to co-administration. Variable TSH levels despite administration reminders suggested variable adherence.

Due to risk of progression of pulmonary metastases and the potential for underlying pulmonary fibrosis from previous radioiodine ablations, respiratory status...
was closely monitored by exercise tolerance, exertional pulse oximetry and formal lung function testing, without abnormality.

**Outcome and follow-up**

At 34 weeks of gestation, the patient presented in preterm labour, progressing rapidly to a normal birth of a healthy male child weighing 2380 g. Breastfeeding was established on discharge, with an intention to continue for 3 months. The child’s TSH was within normal limits. Maternal thyroglobulin 5 months post-partum was 11 µg/L with suppressed TSH. WBS after 3.8 GBq of $^{131}$I administered 7 months post-partum continued to show radioiodine avid pulmonary metastases. Although there were some areas of increased focal uptake of radioiodine, the overall pulmonary uptake was not significantly different to the pre-pregnancy WBS. There were no new areas of abnormal radioiodine uptake. A concurrent CT chest showed maximum pulmonary nodule size of 3 mm, unchanged from ante-partum.

**Discussion**

**Pregnancy and newly diagnosed thyroid cancer**

Thyroid cancer identified during pregnancy most commonly presents as a thyroid nodule, noted either coincidentally or with local symptoms. As the majority of cases are localised to the thyroid (1), the primary management decision is usually the timing of thyroidectomy – either during pregnancy or in the post-partum period – and whether the delay to any planned radioiodine therapy imposed by nursing or breastfeeding is acceptable. These issues are reviewed in recently published guidelines of the American Thyroid Association (2).

Several observations raise concern that pregnancy may reflect a proliferative environment for differentiated thyroid cancer (DTC). The known three-fold increased incidence of DTC in women of reproductive age suggests the involvement of reproductive hormones as thyroid growth factors, confirmed by cellular studies demonstrating proliferative effects of oestrogen on benign and malignant thyrocytes, mediated by oestrogen receptors (3). Studies of serial thyroid ultrasound in pregnant women demonstrate that pregnancy stimulates the formation and growth of thyroid nodules (4), although the absolute magnitude of nodule growth was small. Additionally, the glycoprotein hormone hCG can cross-stimulate the TSH receptor due to structural homology and a common alpha subunit, which may mediate further stimulatory effects on thyrocytes.

Despite these concerns, most clinical outcome data show no difference in the rate of recurrence or long-term survival of women with well-differentiated thyroid cancer identified during pregnancy (1, 2, 5). Two smaller studies noted DTC diagnosed during pregnancy was associated with higher rates of persistent disease and relapse, although possible confounders have been identified (2).

**Pregnancy and established DTC with known distant metastases**

DTC with distant metastases present during pregnancy is uncommon, occurring in 2–3% of pregnancies complicated by thyroid cancer (1, 5). To our knowledge, there are no specific guidelines for the prospective management of pregnancy in women with DTC with distant metastases identified prior to pregnancy or at conception. Recently, three large studies retrospectively examined the effect of pregnancy in survivors of thyroid cancer (2). Of 163 women studied, 9 had residual structural disease pre-conception (8 with cervical nodes, 1 with small volume lung metastases), highlighting the uncommon circumstances of our case. Thus, in the remainder of this article, we discuss clinical management principles for such patients, using parallels from the case vignette.

**Informed discussion of risk: balancing maternal and foetal wellbeing**

Active malignancy during a pregnancy may present a challenging management paradigm, with most decisions either prioritising maternal or foetal wellbeing, sometimes at the expense of the other (6). In pregnancy
complicated by metastatic thyroid cancer, an important unquantifiable risk to maternal health is the potential for accelerated tumour growth due to proliferative effects of oestrogen, hCG and possibly progesterone on metastases, as discussed previously. Additionally, the duration of pregnancy and subsequent breastfeeding may delay planned radioiodine treatment and potentially result in disease progression. Radioiodine uptake is significantly increased in lactating mammary tissue, and subsequent radioiodine treatment should be deferred for at least 3 months after cessation of lactation (2). Conversely, foetal health may be compromised by maternal thyroid status (both hypothyroidism and hyperthyroidism, discussed below), the potential for radiation exposure from residual radioiodine or the need for premature delivery in the case of maternal comorbidity.

This patient’s large radioiodine dose 7 months prior to conception raises concern of residual radiation exposure to the foetus. Recent guidelines recommend deferring pregnancy for 6–12 months after radioiodine (2). Shorter time intervals may increase the risk of miscarriage; however, there is a lack of evidence demonstrating adverse pregnancy or foetal outcomes, including congenital abnormality.

**Levothyroxine replacement: goals, risks and pitfalls**

Physiologic requirements for thyroid hormone rise in early pregnancy due to doubling of thyroid binding globulin by oestrogen and expansion of plasma volume. Hypothyroid women must increase exogenous levothyroxine to compensate, usually by 30% at the time of conception (7), and pre-pregnancy counselling of such patients is mandatory. Monthly monitoring of thyroid function tests to allow early dose titration is recommended.

Maternal hypothyroidism during pregnancy may have deleterious effects on the foetus, particularly neurocognitive development. A study by Haddow (8) found that maternal hypothyroidism during pregnancy was associated with reduced IQ (mean 4 points) in offspring. However, this effect was most pronounced (mean IQ difference 7 points) in the subset of women whose hypothyroidism was untreated for the duration of pregnancy, and it is possible that prompt treatment may ameliorate this effect. Untreated hypothyroidism is also associated with increased risk of early pregnancy loss, and other obstetric complications including gestational hypertension, pre-eclampsia and preterm labour.

Although hyperthyroidism in pregnancy is associated with hypertension, low birth weight and preterm birth, subclinical hyperthyroidism with normal free thyroid hormones was not associated with an increased rate of adverse pregnancy outcomes in a large cohort study (9). In our patient, a suppressed TSH was targeted to minimise growth stimulus for cancer metastases; however, this may have contributed to premature labour. The strong correlation between TSH and level of thyroglobulin in this pregnancy (Fig. 2) supports the premise of TSH suppression to limit cancer growth in this patient.

Levothyroxine is poorly absorbed from the gut in the presence of iron and calcium supplements that are common components of pregnancy multivitamins. Our practice is to instruct patients to take levothyroxine on an empty stomach in the morning, and vitamins in the evening, to avoid inadvertent hypothyroidism due to malabsorption.

**Monitoring for disease progression: methods and endpoints**

Progression of metastatic DTC can be determined outside of pregnancy using structural imaging techniques such as computed tomography or functional imaging using radioiodine or F-fluorodeoxyglucose positron emission tomography. However, these modalities are not appropriate in pregnancy due to risk of ionising radiation to the foetus. Serial neck ultrasound is useful for monitoring for growth of any known structural disease in the neck and is safe in pregnancy.

Interpretation of serum thyroglobulin as a surrogate of tumour progression is complicated in pregnancy due to the stimulatory effect of physiologic fluctuations in TSH and thyroid hormone levels, and thus minor changes are unlikely to provide sufficient information to inform major clinical decisions (2). Widely variable TSH levels with corresponding changes in thyroglobulin were present in our patient, which confirmed tumoural TSH responsiveness but hindered meaningful assessment of tumour progression.

With these limitations, there was no objective evidence that this patient’s pregnancy resulted in progression or worsening of her thyroid cancer.

**Prognosis of metastatic DTC**

Despite a variable prognosis, metastatic DTC has a favourable long-term survival compared to other cancers, particularly when diagnosed in childhood. A cohort study of 72 children with DTC (10), including 13 with lung metastases at diagnosis, found that 6 patients (including 2 patients presenting with pulmonary metastases) died over a median 13 years of follow-up, 12–33 years after initial...
treatment. The 10-year survival for all patients in this cohort was 98%, falling to 90% at 20 years. Nonetheless, a standardised mortality ratio of 8.1 persists.

**Conclusions**

Metastatic DTC presents a challenging management paradigm in pregnancy. Ultimately, all decisions reflect an acceptance of the known and unknown risks balanced between mother and foetus, made through comprehensive engagement between clinicians in a multidisciplinary team, centred on the patient and her family. As similar cases are few, data to inform risk must be extrapolated from available evidence and clinician judgement.

**Declaration of interest**
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

**Funding**
This work was supported by the Hunter-New-England Clinical Research Fellowship and the AVANT Doctors-in-Training Research Scholarship Program (to C R).

**Patient consent**
Written informed consent was obtained from the patient prior to publication.

**Author contribution statement**
C R, K M, A W, S G and K W cared for the patient. C R drafted the manuscript with K W, with review and revision from K M, A W, S G and R S. All authors have reviewed the final manuscript.

**References**

1 Moosa M & Mazzaferri EL 1997 Outcome of differentiated thyroid cancer diagnosed in pregnant women. *Journal of Clinical Endocrinology and Metabolism* **82** 2862–2866. (doi:10.1210/jcem.82.9.4247)


